Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

CCK denotes cholecystokinin, GI gastrointestinal, GLP-1 glucagon-like peptide 1, and PYY peptide YY. Hunger is controlled by redundant neuroendocrine circuitries that maintain metabolic balance.

Eli Lilly has decided to wait for the readout of the second of its two phase 3 trials for tirzepatide in obesity, rather than filing on the strength of its first, positive study.

Jessica DeBenedetto has only been on compounded tirzepatide for a couple of weeks, but she already feels like it’s a life-changer. Her doctor prescribed the cheaper, generic version of the ...

including those already presently developed for GLP-1 and newer ones for PYY, pancreatic polypeptide and glucagon. Some promising recent developments are outlined below. Sitagliptin USA ...

In November 2023, the Food and Drug Administration (FDA) approved Zepbound (tirzepatide) for long-term weight management. Tirzepatide has been approved for treating type 2 diabetes under the trade ...

Tirzepatide is under clinical development by Eli Lilly and Co and currently in Pre-Registration for Obstructive Sleep Apnea. According to GlobalData, Pre-Registration drugs for Obstructive Sleep Apnea ...

Weight loss drugs like Ozempic and wegovy have become global sensation. In the recent years, companies like Novo Nordisk and Eli Lilly have GLP-1 agonists and dual GLP-1/GIP receptor agonists that ...

The injected Zepbound® produced a total of 38 adverse events across the study group of 9 persons, whereas the oral DehydraTECH-tirzepatide only produced 20 adverse events, a reduction of 47%.